Literature DB >> 16287438

Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer.

Gerhardt Attard1, Arie S Belldegrun, Johann S de Bono.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16287438     DOI： 10.1111/j.1464-410X.2005.05821.x

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  65 in total

1.  Hedgehog Proteins Consume Steroidal CYP17A1 Antagonists: Potential Therapeutic Significance in Advanced Prostate Cancer.

Authors:  Brandon M Bordeau; Daniel A Ciulla; Brian P Callahan
Journal:  ChemMedChem       Date:  2016-07-20       Impact factor: 3.466

Review 2.  [Randomized controlled trials terminated prematurely: beneficial therapy effects].

Authors:  L A Kluth; M Rink; S A Ahyai; M Fisch; S F Shariat; P Dahm
Journal:  Urologe A       Date:  2013-08       Impact factor: 0.639

Review 3.  Therapy of Advanced Prostate Cancer: Targeting the Androgen Receptor Axis in Earlier Lines of Treatment.

Authors:  Harsh Shah; Ulka Vaishampayan
Journal:  Target Oncol       Date:  2018-12       Impact factor: 4.493

Review 4.  [What comes after docetaxel?].

Authors:  C-H Ohlmann; M Stöckle
Journal:  Urologe A       Date:  2010-01       Impact factor: 0.639

5.  Prostate cancer: The influence of steroid metabolism on CYP17A1 inhibitor activity.

Authors:  Frank Claessens; Lisa Moris
Journal:  Nat Rev Urol       Date:  2017-08-08       Impact factor: 14.432

6.  Androgens regulate SMAD ubiquitination regulatory factor-1 expression and prostate cancer cell invasion.

Authors:  Xiaokun Gang; Guixia Wang; Haojie Huang
Journal:  Prostate       Date:  2015-01-28       Impact factor: 4.104

7.  The changing landscape in the treatment of metastatic castration-resistant prostate cancer.

Authors:  Joelle El-Amm; Jeanny B Aragon-Ching
Journal:  Ther Adv Med Oncol       Date:  2013-01       Impact factor: 8.168

8.  Transcription factor KLLN inhibits tumor growth by AR suppression, induces apoptosis by TP53/TP73 stimulation in prostate carcinomas, and correlates with cellular differentiation.

Authors:  Yu Wang; Deepa Radhakrishnan; Xin He; Donna M Peehl; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2013-02-05       Impact factor: 5.958

9.  Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors:  Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal:  N Engl J Med       Date:  2012-12-10       Impact factor: 91.245

10.  Update on options for treatment of metastatic castration-resistant prostate cancer.

Authors:  Prakash Vishnu; Winston W Tan
Journal:  Onco Targets Ther       Date:  2010-06-24       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.